FDA Approves POMALIDOMIDE — Teva Pharmaceuticals, Inc.

# FDA Approves Generic Version of Pomalidomide; Teva Gains Market Entry Teva Pharmaceuticals, Inc. received FDA approval for its generic oral pomalidomide formulation (ANDA209956) on May 4, 2022, positioning the company to capture market share in the multiple myeloma treatment segment as patent protections on the branded Pomalyst decline. The approval could intensify pricing competition in the immunomodulatory drug category while expanding patient access to this critical cancer therapy.